Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Penn State Cancer Institute, Hershey, PA , United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Hershey, PA
Treatments:ChemotherapyHospital:Penn State Cancer Institute
Drugs:Journal:Link
Date:Jan 2008

Description:

Patients: This phase III study involved 444 patients with stage IIIB/IV non-small-cell lung cancer. The median age was 65, ranging from 28 to 92 years old. There were more men than women (63% of patients were men).

Treatment: Patients were treated the chemotherapy drugs paclitaxel and carboplatin. There were two groups or ‘Arms’ in this study, and the patients in each arm received different amounts of these drugs for different lengths of time.

Toxicity: One patient died from pneumonia, and this death was considered related to the drug treatment. Grade 3 and 4 toxicities included neutropenia, anemia, thrombocytopenia, febrile neutropenia, neuropathy, pneumonia, dehydration, nausea, and fatigue. Neutropenia and neuropathy were the most common grade 3 or 4 toxicities reported.

Results: The median overall survival was 8.9 months (38.6 weeks) for patients in Arm 1, and 9.9 months (42.9 weeks) for patients in Arm 2.

Support: This study was supported by funds from Bristol-Myers Squibb, which markets paclitaxel as Taxol®

Correspondence: Dr. Chandra P. Belani



Back